OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC
Filed with ASX · · 2 pages · English
Sydney, Australia, 29 June 2022:OncoSil Medical Limited (ASX: OSL) (OncoSilor theCompany) is pleased to announce that the Principal Investigator of the PanCO study will be presenting both an oral and poster presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) on 29 June 2022. The presentation is titled “Comparison of resected vs. non-resected patients with unresectable locall
Earlier from OncoSil Medical
- Entitlement Offer Results and Shortfall Notification
- OncoSil Entitlement Offer Booklet
- Clarification Of Non-Renouncable Entitlement Offer Details
- OncoSil Launches $10m Capital Raising
- OncoSil Signs Commercial Agreement With Hospital In Spain
Later from OncoSil Medical
- FY 2023 Strategic Update
- Bupa UK Approves Reimbursement for OncoSil in the UK
- Patient treated in Spain proceeds to successful resection
- Monthly Activities/Appendix 4C Cash Flow Report
- Investor Presentation
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical